Related Experiment Video

Updated: Aug 9, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Disturbances of glucose and lipid metabolism during treatment with new generation antipsychotics

Maria A Rettenbacher1

  • 1Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria. maria.rettenbacher@uibk.ac.at

Current Opinion in Psychiatry
|April 28, 2006
PubMed
Abstract

Insights

Second-generation antipsychotics can alter lipid and glucose metabolism. This review examines these metabolic changes, their mechanisms, and management strategies in patients.

Area of Science:

  • Metabolic disorders
  • Pharmacology
  • Psychiatry

Background:

  • Second-generation antipsychotics (SGAs) are widely used for psychiatric disorders.
  • SGAs are associated with significant adverse metabolic effects.
  • These effects impact patient health and treatment adherence.

Purpose of the Study:

  • To review recent literature on lipid and glucose metabolism alterations in patients treated with SGAs.
  • To explore potential mechanisms underlying these metabolic changes.
  • To discuss prevention and management strategies for SGA-induced metabolic side effects.

Main Methods:

  • Literature review of recent studies.
  • Focus on prospective controlled trials.
  • Analysis of receptor profiles and their relation to metabolic alterations.

Main Results:

  • Numerous reports exist, but prospective controlled trials are limited.
  • Investigates potential differences in metabolic alterations among various SGAs.
  • Highlights the role of receptor profiles in mediating these effects.

Conclusions:

  • Adverse metabolic effects of SGAs are clinically relevant.
  • These effects significantly impact the physical health of schizophrenia patients.
  • Addressing metabolic concerns is crucial for treatment adherence and public health.

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications